{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.2","upperLimit":"55.5","value":"39.0"},{"groupId":"OG001","lowerLimit":"21.1","upperLimit":"78.9","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Objective response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.6","upperLimit":"59.3","value":"41.2"},{"groupId":"OG001","lowerLimit":"15.7","upperLimit":"84.3","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Intracranial objective response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Objective response (OR) refers to confirmed CR or PR according to RECIST version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. CR was defined as the disappearance of all non-lymph node target lesions (where all target lesions are recorded with a length of 0 mm on Target Lesions eCRF). Any pathological lymph nodes (recorded as target lesion) must have reduction in short axis to \\<10 mm. PR was defined as a 30 % or more decrease in SLD of target lesions, taking as reference the baseline SLD. Results presented here were based on independent central review.","dispersionType":"95% Confidence Interval","groups":[{"description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.","id":"OG000","title":"ALK Positive Population (Phase 1)"},{"description":"This reporting arm includes all Phase 1 participants who had documented ROS1 rearrangement.","id":"OG001","title":"ROS1 Positive Population (Phase 1)"}],"paramType":"NUMBER","populationDescription":"The ITT analysis set was used for overall response assessment and included all enrolled participants with documented ALK or ROS1 rearrangement who received at least 1 dose of PF-06463922; participants with CNS metastases in the ITT analysis set was used for intracranial response assessment. Here, \"Number Analyzed\" signifies participants analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From start of study treatment until CR or PR (maximum of 8 years approximately)","title":"Percentage of Participants With Overall and Intracranial Objective Response (Phase 1)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}